ArticleJournal of inflammation research2026
Association of the Neutrophil to High-Density Lipoprotein Cholesterol Ratio and Platelet to High-Density Lipoprotein Cholesterol Ratio with Early Vascular Aging.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This cross-sectional study aimed to investigate the association of complete blood count parameters and lipid metabolism‑related inflammatory indices with early vascular aging (EVA). Methods: A total of 1114 participants were included with an overall EVA prevalence of 19.6%. Logistic regression was adopted to assess the independent associations of neutrophil to high-density lipoprotein cholesterol ratio (NHR) and platelet to high-density lipoprotein cholesterol ratio (PHR) with EVA after adjusting for traditional cardiovascular risk factors. Restricted cubic spline (RCS) models were applied to examine nonlinear relationships. Subgroup analyses were conducted to evaluate effect modification, and decision curve analysis (DCA) was used to assess the net benefit for risk stratification. Results: In the fully adjusted model, both NHR (OR = 1.583, 95% CI: 1.078-2.327, P = 0.019) and PHR (OR = 2.050, 95% CI: 1.325-3.173, P = 0.001) remained independently associated with increased odds of EVA. The RCS analysis did not reveal significant nonlinear relationships for either biomarker (P for non-linearity > 0.05), suggesting that the associations were adequately captured by linear models. Subgroup analyses revealed that the positive association between NHR and EVA risk was more pronounced in men and smokers. For PHR, there was no significant interaction among different subgroups. DCA demonstrated that both NHR and PHR conferred modest net benefit gains (maximum 0.0127 and 0.0162, respectively) across clinically relevant threshold probabilities. Conclusion: In this cross‑sectional population, both NHR and PHR were independently associated with EVA, with essentially linear dose‑response relationships. The association between NHR and EVA was particularly significant in men and smokers, showing population heterogeneity. Both indices provided a modest net benefit for identifying individuals with EVA, but the modest magnitude of this benefit suggests limited immediate clinical utility. Limitations include the cross‑sectional design and single‑center cohort, which limit causal inference and generalizability. Further prospective, multi‑center studies are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.